首页期刊导航|中华医学杂志(英文版)
期刊信息/Journal information
中华医学杂志(英文版)
中华医学会
中华医学杂志(英文版)

中华医学会

照日格图

半月刊

0366-6999

renlihua@cma.org.cn

010-85158321

100710

北京市东城区东四西大街42号

中华医学杂志(英文版)/Journal Chinese Medical JournalCSCDCSTPCD北大核心SCI
查看更多>>1887年创刊,中华医学会主办。中华医学杂志英文版(Chinese Medical Journal)是中华医学会会刊,是中国惟一被SCI核心版收录、具有百年以上历史的医学期刊。重点报道我国医学各学科最新进展和高水平科研成果,目前已被《科学引文索引(SCI)》、《医学索引(IM)》、Medline等国际著名检索系统收录。2009年SCI影响因子0.952,SCI被引频次3407。2010年被国际医学期刊编辑委员会(ICMJE)吸收为新成员。多次获得国家期刊奖、科协专项基金、自然基金等奖项和资助。实行全文上网 (),网上投稿审稿()。
正式出版
收录年代

    Chinese expert consensus on sedation and analgesia for neurocritical care patients

    Linlin ZhangShuai LiuShuya WangJian-Xin Zhou...
    1261-1263页

    Chinese expert consensus on the clinical application of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease

    The Expert Group of Chinese Expert Consensus on the Clinical Application of Sodium-glucose CotranspoFan Fan HouChuanming Hao
    1264-1266页

    Consensus of Chinese experts on glioma multidisciplinary team management(2nd edition)

    Jinsong WuZhirui ZhouZanyi WuZhiwei Tang...
    1267-1270页

    The switch triggering the invasion process:Lipid metabolism in the metastasis of hepatocellular carcinoma

    Jiaqian ZhangZhicheng ZhangZhangfan WuYufei Wang...
    1271-1284页
    查看更多>>摘要:In humans,the liver is a central metabolic organ with a complex and unique histological microenvironment.Hepatocellular car-cinoma(HCC),which is a highly aggressive disease with a poor prognosis,accounts for most cases of primary liver cancer.As an emerging hallmark of cancers,metabolic reprogramming acts as a runaway mechanism that disrupts homeostasis of the affected organs,including the liver.Specifically,rewiring of the liver metabolic microenvironment,including lipid metabolism,is driven by HCC cells,propelling the phenotypes of HCC cells,including dissemination,invasion,and even metastasis in return.The resulting formation of this vicious loop facilitates various malignant behaviors of HCC further.However,few articles have comprehensively summarized lipid reprogramming in HCC metastasis.Here,we have reviewed the general situation of the liver microenvironment and the physiological lipid metabolism in the liver,and highlighted the effects of different aspects of lipid metabolism on HCC metastasis to explore the underlying mechanisms.In addition,we have recapitulated promising therapeutic strategies targeting lipid metabolism and the effects of lipid metabolic reprogramming on the efficacy of HCC systematical therapy,aiming to offer new perspectives for targeted therapy.

    Chimeric antigen receptor-immune cells against solid tumors:Structures,mechanisms,recent advances,and future developments

    Xudong LiWei LiLinping XuYongping Song...
    1285-1302页
    查看更多>>摘要:The advent of chimeric antigen receptor(CAR)-T cell immunotherapies has led to breakthroughs in the treatment of hematological malignancies.However,their success in treating solid tumors has been limited.CAR-natural killer(NK)cells have several advantages over CAR-T cells because NK cells can be made from pre-existing cell lines or allogeneic NK cells with a mismatched major histocompatibility complex(MHC),which means they are more likely to become an"off-the-shelf"product.Moreover,they can kill cancer cells via CAR-dependent/independent pathways and have limited toxicity.Macrophages are the most malleable immune cells in the body.These cells can efficiently infiltrate into tumors and are present in large numbers in tumor microenvironments(TMEs).Importantly,CAR-macrophages(CAR-Ms)have recently yielded exciting preclinical results in several solid tumors.Nevertheless,CAR-T,CAR-NK,and CAR-M all have their own advantages and limitations.In this review,we systematically discuss the current status,progress,and the major hurdles of CAR-T cells,CAR-NK cells,and CAR-M as they relate to five aspects:CAR structure,therapeutic mechanisms,the latest research progress,current challenges and solutions,and comparison according to the existing research in order to provide a reasonable option for treating solid tumors in the future.

    Hematopoietic aging:Cellular,molecular,and related mechanisms

    Li YeChuan TianYe LiHang Pan...
    1303-1312页
    查看更多>>摘要:Aging is accompanied by significant inhibition of hematopoietic and immune system function and disruption of bone marrow structure.Aging-related alterations in the inflammatory response,immunity,and stem cell niches are at the root of hematopoietic aging.Understanding the molecular mechanisms underlying hematopoietic and bone marrow aging can aid the clinical treatment of aging-related diseases.In particular,it is unknown how the niche reprograms hematopoietic stem cells(HSCs)in an age-dependent manner to maintain normal hematopoiesis in elderly individuals.Recently,specific inhibitors and blood exchange methods have been shown to reshape the hematopoietic niche and reverse hematopoietic aging.Here,we present the latest scientific discoveries related to hematopoietic aging and hematopoietic system rejuvenation,discuss the relationships between hematopoietic niche aging and HSC aging,and describe related studies on stem cell-mediated regulation of hematopoietic aging,aiming to provide new ideas for further study.

    Epidemic intelligence trinity:Detection,risk assessment,and early warning

    Ting ZhangLuzhao FengShengjie LaiZhihang Peng...
    1313-1315页

    Development and validation of a novel criterion of histologic healing in ulcerative colitis defined by inflammatory cell enumeration in lamina propria mucosa:A multicenter retrospective cohort in China

    Han GaoKangsheng PengYadi ShiShenshen Zhu...
    1316-1323页
    查看更多>>摘要:Background:Histological healing is closely associated with improved long-term clinical outcomes and lowered relapses in patients with ulcerative colitis(UC).Here,we developed a novel diagnostic criterion for assessing histological healing in UC patients.Methods:We conducted a retrospective cohort study in UC patients,whose treatment was iteratively optimized to achieve mucosal healing at Shanghai Tenth People's Hospital of Tongji University from January 2017 to May 2022.We identified an inflammatory cell enumeration index(ICEI)for assessing histological healing based on the proportions of eosinophils,CD177+neutrophils,and CD40L+T cells in the colonic lamina propria under high power field(HPF),and the outcomes(risks of symptomatic relapses)of achieving histological remission vs.persistent histological inflammation using Kaplan-Meier curves.Intrareader reliability and inter-reader reliability were evaluated by each reader.The relationships to the changes in the Nancy index and the Geboes score were also assessed for responsiveness.The ICEI was further validated in a new cohort of UC patients from other nine university hospitals.Results:We developed an ICEI for clinical diagnosis of histological healing,i.e.,Y=1.701X1+0.758X2+1.347X3-7.745(X1,X2,and X3 represent the proportions of CD177+neutrophils,eosinophils,and CD40L+T cells,respectively,in the colonic lamina propria under HPF).The receiver operating characteristics curve(ROC)analysis revealed that Y<-0.391 was the cutoff value for the diagnosis of histological healing and that an area under the curve(AUC)was 0.942(95%confidence interval[CI]:0.905-0.979)with a sensitivity of 92.5%and a specificity of 83.6%(P<0.001).The intraclass correlation coefficient(ICC)for the intrareader reliability was 0.855(95%CI:0.781-0.909),and ICEI had good inter-reader reliability of 0.832(95%CI:0.748-0.894).During an 18-month follow-up,patients with histological healing had a substantially better outcome compared with those with unachieved histological healing(P<0.001)using ICEI.During a 12-month follow-up from other nine hospitals,patients with histological healing also had a lower risk of relapse than patients with unachieved histological healing.Conclusions:ICEI can be used to predict histological healing and identify patients with a risk of relapse 12 months and 18 months after clinical therapy.Therefore,ICEI provides a promising,simplified approach to monitor histological healing and to predict the prognosis of UC.

    Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China:A nationwide,multi-center,population-based cross-sectional study

    Weiyu ZhangHuixin LiuMing LiuShi Ying...
    1324-1331页
    查看更多>>摘要:Background:Cardiovascular disease(CVD)has emerged as the leading cause of death from prostate cancer(PCa)in recent decades,bringing a great disease burden worldwide.Men with preexisting CVD have an increased risk for major adverse cardio-vascular events when treated with androgen deprivation therapy(ADT).The present study aimed to explore the prevalence and risk evaluation of CVD among people with newly diagnosed PCa in China.Methods:Clinical data of newly diagnosed PCa patients were retrospectively collected from 34 centers in China from 2010 to 2022 through convenience sampling.CVD was defined as myocardial infarction,arrhythmia,heart failure,stroke,ischemic heart disease,and others.CVD risk was estimated by calculating Framingham risk scores(FRS).Patients were accordingly divided into low-,medium-,and high-risk groups.x2 or Fisher's exact test was used for comparison of categorical variables.Results:A total of 4253 patients were enrolled in the present study.A total of 27.0%(1147/4253)of patients had comorbid PCa and CVD,and 7.2%(307/4253)had two or more CVDs.The enrolled population was distributed in six regions of China,and approximately 71.0%(3019/4253)of patients lived in urban areas.With imaging and pathological evaluation,most PCa patients were diagnosed at an advanced stage,with 20.5%(871/4253)locally progressing and 20.5%(871/4253)showing metastasis.Most of them initiated prostatectomy(46.6%,1983/4253)or regimens involving ADT therapy(45.7%,1944/4253)for prostate cancer.In the present PCa cohort,43.1%(1832/4253)of patients had hypertension,and half of them had poorly controlled blood pressure.With FRS stratification,as expected,a higher risk of CVD was related to aging and metabolic disturbance.However,we also found that patients with treatment involving ADT presented an originally higher risk of CVD than those without ADT.This was in accordance with clinical practice,i.e.,aged patients or patients at advanced oncological stages were inclined to accept systematic integrative therapy instead of surgery.Among patients who underwent medical castration,only 4.0%(45/1118)received gonadotropin releasing hormone antagonists,in stark contrast to the grim situation of CVD prevalence and risk.Conclusions:PCa patients in China are diagnosed at an advanced stage.A heavy CVD burden was present at the initiation of treatment.Patients who accepted ADT-related therapy showed an original higher risk of CVD,but the awareness of cardiovascu-lar protection was far from sufficient.

    Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma:A propensity-matched real-world study

    Shujung HsuYencheng ChaoYong HuYang Zhang...
    1332-1342页
    查看更多>>摘要:Background:To address the need for immunotherapy in patients with advanced primary hepatocellular carcinoma(HCC),com-bination with radiotherapy(RT)has emerged as a promising strategy.In preclinical studies,irradiated tumors released tumor antigens to synergistically increase the antitumor effect of immunotherapy.Hence,we investigated whether RT enhances the efficacy of anti-programmed death receptor-1(PD-1)inhibitors in advanced HCC in real-world practice.Methods:Between August 2018 and June 2021,172 patients with advanced primary HCC were enrolled in the tertiary center(Zhongshan Hospital of.Fudan University);95 were treated with a combination of RT and the inhibitor of PD-1(RT-PD1 cohort),and 77 were administered anti-PD-1 therapy(PD1 cohort).The first cycle of PD-1 inhibitors was administered within 60 days or concurrently with RT.Propensity score matching for bias reduction was used to evaluate the clinical outcomes.Results:Among 71 propensity-matched pairs,median progression-free survival was 5.7 months in the RT-PD1 cohort vs.2.9 months in the PD1 cohort(P<0.001).Median overall survival was 20.9 months in the RT-PD1 cohort vs.11.2 months in the PD1 cohort(P=0.018).Compared with patients in the PD1 cohort,patients in the RT-PD1 cohort had significantly higher objective response rates(40.8%,29/71 vs.19.7%,14/71,P=0.006)and disease control rates(62.0%,44/71 vs.31.0%,22/71,P<0.001).The incidences of toxic effects were not significantly different between the two cohorts.Conclusions:RT plus anti-PD-1 therapy is well tolerated.RT enhances the efficacy of anti-PD-1 therapy in patients with advanced primary HCC by improving survival outcomes without increased toxic effects.